Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas

Nature Medicine

Volumn 20, Issue 3, 2014, Pages 283-290

  Afshar Sterle, Shoukat ^a,b   Zotos, Dimitra ^a,b   Bernard, Nicholas J ^a,b   Scherger, Anna K ^a,b   Rödling, Lisa ^a,b   Alsop, Amber E ^a,b   Walker, Jennifer ^a,b   Masson, Frederick ^a,b   Belz, Gabrielle T ^a,b   Corcoran, Lynn M ^a,b   O'reilly, Lorraine A ^a,b   Strasser, Andreas ^a,b   Smyth, Mark J ^c,d   Johnstone, Ricky ^b,e   Tarlinton, David M ^a,b   Nutt, Stephen L ^a,b   Kallies, Axel ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CD28 ANTIGEN; FAS LIGAND; PROTEIN BCL 6; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; BLIMP1 GENE; CANCER CONTROL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; IMMUNOSURVEILLANCE; LYMPHOMA CELL; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; TRANSGENE;

MUS;

ANIMALS; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FAS LIGAND PROTEIN; FLOW CYTOMETRY; GENES, TUMOR SUPPRESSOR; IMMUNOLOGIC SURVEILLANCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MICE, TRANSGENIC; MUTATION; T-LYMPHOCYTES; TRANSCRIPTION FACTORS;

EID: 84896121866     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3442     Document Type: Article

References (77)

1. Schneider, C., Pasqualucci, L. & Dalla-Favera, R. Molecular pathogenesis of diffuse large B-cell lymphoma. Semin. Diagn. Pathol. 28, 167-177 (2011
2. Nogai, H., Dorken, B. & Lenz, G. Pathogenesis of non-Hodgkin's lymphoma. J. Clin. Oncol. 29, 1803-1811 (2011
3. Rosenwald, A. et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198, 851-862 (2003
4. Frick, M., Dorken, B. & Lenz, G. New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma. Best Pract. Res. Clin. Haematol. 25, 3-12 (2012
5. Alizadeh, A.A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000
6. Lenz, G. & Staudt, L.M. Aggressive lymphomas. N. Engl. J. Med. 362, 1417-1429 (2010
7. Rui, L., Schmitz, R., Ceribelli, M. & Staudt, L.M. Malignant pirates of the immune system. Nat. Immunol. 12, 933-940 (2011
8. Shapiro-Shelef, M. et al. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 19, 607-620 (2003
9. Kallies, A. et al. Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1. Immunity 26, 555-566 (2007
10. Mandelbaum, J. et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 18, 568-579 (2010
11. Calado, D.P. et al. Constitutive canonical NF-?B activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell 18, 580-589 (2010
12. Ye, B.H. et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 262, 747-750 (1993
13. Iqbal, J. et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 21, 2332-2343 (2007
14. Dent, A.L., Shaffer, A.L., Yu, X., Allman, D. & Staudt, L.M. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 276, 589-592 (1997
15. Muramatsu, M. et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102, 553-563 (2000
16. Pasqualucci, L. et al. BCL-6 mutations in normal germinal center B cells: Evidence of somatic hypermutation acting outside Ig loci. Proc. Natl. Acad. Sci. USA 95, 11816-11821 (1998
17. Shen, H.M., Peters, A., Baron, B., Zhu, X. & Storb, U. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 280, 1750-1752 (1998
18. Yamane, A. et al. Deep-sequencing identification of the genomic targets of the cytidine deaminase AID and its cofactor RPA in B lymphocytes. Nat. Immunol. 12, 62-69 (2011
19. Cattoretti, G. et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 7, 445-455 (2005
20. Grulich, A.E., van Leeuwen, M.T., Falster, M.O. & Vajdic, C.M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-Analysis. Lancet 370, 59-67 (2007
21. Schreiber, R.D., Old, L.J. & Smyth, M.J. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011
22. Challa-Malladi, M. et al. Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 20, 728-740 (2011
23. Rimsza, L.M. et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: A follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103, 4251-4258 (2004
24. Smyth, M.J. et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192, 755-760 (2000
25. Street, S.E. et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and ?d T cells. J. Exp. Med. 199, 879-884 (2004
26. Kallies, A. et al. Plasma cell ontogeny defined by quantitative changes in blimp-1 expression. J. Exp. Med. 200, 967-977 (2004
27. Kutok, J.L. & Wang, F. Spectrum of Epstein-Barr virus-Associated diseases. Annu. Rev. Pathol. 1, 375-404 (2006
28. Lee, K.S., Groshong, S.D., Cool, C.D., Kleinschmidt-DeMasters, B.K. & van Dyk, L.F. Murine gammaherpesvirus 68 infection of IFN? unresponsive mice: A small animal model for gammaherpesvirus-Associated B-cell lymphoproliferative disease. Cancer Res. 69, 5481-5489 (2009
29. D'Costa, K. et al. Blimp1 is limiting for transformation in a mouse plasmacytoma model. Blood 113, 5911-5919 (2009
30. Pasqualucci, L. et al. AID is required for germinal center-derived lymphomagenesis. Nat. Genet. 40, 108-112 (2008
31. Stopeck, A.T. et al. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin. Cancer Res. 6, 3904-3909 (2000
32. Salek-Ardakani, S. et al. B cell-specific expression of B7-2 is required for follicular TH cell function in response to vaccinia virus. J. Immunol. 186, 5294-5303 (2011
33. Victora, G.D. et al. Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. Cell 143, 592-605 (2010
34. Man, K. et al. The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T cells. Nat. Immunol. 14, 1155-1165 (2013
35. Kaech, S.M. & Cui, W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat. Rev. Immunol. 12, 749-761 (2012
36. Burnet, F.M. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1-27 (1970
37. Willimsky, G. & Blankenstein, T. The adaptive immune response to sporadic cancer. Immunol. Rev. 220, 102-112 (2007
38. Zhang, B. et al. Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell 148, 739-751 (2012
39. Pasqualucci, L. et al. Expression of the AID protein in normal and neoplastic B cells. Blood 104, 3318-3325 (2004
40. Kitano, M. et al. Bcl6 protein expression shapes pre-germinal center B cell dynamics and follicular helper T cell heterogeneity. Immunity 34, 961-972 (2011
41. Kolar, G.R., Mehta, D., Pelayo, R. & Capra, J.D. A novel human B cell subpopulation representing the initial germinal center population to express AID. Blood 109, 2545-2552 (2007
42. Marshall, J.L. et al. Early B blasts acquire a capacity for Ig class switch recombination that is lost as they become plasmablasts. Eur. J. Immunol. 41, 3506-3512 (2011
43. Kaji, T. et al. Distinct cellular pathways select germline-encoded and somatically mutated antibodies into immunological memory. J. Exp. Med. 209, 2079-2097 (2012
44. Rosenberg, S.A., Restifo, N.P., Yang, J.C., Morgan, R.A. & Dudley, M.E. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8, 299-308 (2008
45. Bolitho, P. et al. Perforin-mediated suppression of B-cell lymphoma. Proc. Natl. Acad. Sci. USA 106, 2723-2728 (2009
46. Koebel, C.M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903-907 (2007
47. Davidson, W.F., Giese, T. & Fredrickson, T.N. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J. Exp. Med. 187, 1825-1838 (1998
48. Stel, A.J. et al. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. J. Immunol. 178, 2287-2295 (2007
49. Pasqualucci, L. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43, 830-837 (2011
50. Lohr, J.G. et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. USA 109, 3879-3884 (2012
51. Straus, S.E. et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 98, 194-200 (2001
52. Müschen, M., Rajewsky, K., Kronke, M. & Kuppers, R. The origin of CD95-gene mutations in B-cell lymphoma. Trends Immunol. 23, 75-80 (2002
53. Kojima, Y. et al. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur. J. Haematol. 76, 465-472 (2006
54. Wang, S.S. et al. Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-?B transcription factors and non-Hodgkin lymphoma risk. PLoS ONE 4, e5360 (2009
55. Harris, J. et al. Cellular (FLICE) like inhibitory protein (cFLIP) expression in diffuse large B-cell lymphoma identifies a poor prognostic subset, but fails to predict the molecular subtype. Hematol. Oncol. 30, 8-12 (2012
56. Novac, N., Baus, D., Dostert, A. & Heinzel, T. Competition between glucocorticoid receptor and NF?B for control of the human FasL promoter. FASEB J. 20, 1074-1081 (2006
57. Esser, M.T., Krishnamurthy, B. & Braciale, V.L. Distinct T cell receptor signaling requirements for perforin-or FasL-mediated cytotoxicity. J. Exp. Med. 183, 1697-1706 (1996
58. Kessler, B. et al. Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas-but not perforin-dependent cytotoxicity or cytokine production. J. Immunol. 161, 6939-6946 (1998
59. He, J.S., Gong, D.E. & Ostergaard, H.L. Stored Fas ligand, a mediator of rapid CTL-mediated killing, has a lower threshold for response than degranulation or newly synthesized Fas ligand. J. Immunol. 184, 555-563 (2010
60. Shanker, A. et al. Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity. Cancer Res. 69, 6615-6623 (2009
61. Kallies, A., Xin, A., Belz, G.T. & Nutt, S.L. Blimp-1 transcription factor is required for the differentiation of effector CD8+ T cells and memory responses. Immunity 31, 283-295 (2009
62. Rosenbaum, H. et al. An E μ-v-Abl transgene elicits plasmacytomas in concert with an activated myc gene. EMBO J. 9, 897-905 (1990
63. Hobeika, E. et al. Testing gene function early in the B cell lineage in mb1-cre mice. Proc. Natl. Acad. Sci. USA 103, 13789-13794 (2006
64. Malissen, M. et al. Altered T cell development in mice with a targeted mutation of the CD3-epsilon gene. EMBO J. 14, 4641-4653 (1995
65. Shahinian, A. et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261, 609-612 (1993
66. Pao, L.I. et al. Functional analysis of granzyme M and its role in immunity to infection. J. Immunol. 175, 3235-3243 (2005
67. Kägi, D. et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369, 31-37 (1994
68. Cretney, E. et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168, 1356-1361 (2002
69. Dalton, D.K. et al. Multiple defects of immune cell function in mice with disrupted interferon-? genes. Science 259, 1739-1742 (1993
70. O' Reilly, L.A. et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 461, 659-663 (2009
71. Szabo, S.J. et al. Distinct effects of T-bet in TH1 lineage commitment and IFN-? production in CD4 and CD8 T cells. Science 295, 338-342 (2002
72. Mittrücker, H.W. et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 275, 540-543 (1997
73. Hogquist, K.A. et al. T cell receptor antagonist peptides induce positive selection. Cell 76, 17-27 (1994
74. Pridans, C. et al. Identification of Pax5 target genes in early B cell differentiation. J. Immunol. 180, 1719-1728 (2008
75. Kupresanin, F. et al. Dendritic cells present lytic antigens and maintain function throughout persistent gamma-herpesvirus infection. J. Immunol. 179, 7506-7513 (2007
76. Schlissel, M.S., Corcoran, L.M. & Baltimore, D. Virus-Transformed pre-B cells show ordered activation but not inactivation of immunoglobulin gene rearrangement and transcription. J. Exp. Med. 173, 711-720 (1991
77. Holler, N. et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol. Cell. Biol. 23, 1428-1440 (2003